Skip to main content
Aurisco Pharmaceutical Co.,Ltd. logo

Aurisco Pharmaceutical Co.,Ltd. — Investor Relations & Filings

Ticker · 605116 ISIN · CNE1000042S4 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 669 across all filing types
Latest filing 2023-08-15 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 605116

About Aurisco Pharmaceutical Co.,Ltd.

https://www.aurisco.com/

Aurisco Pharmaceutical Co.,Ltd. specializes in the development and large-scale manufacturing of complex Active Pharmaceutical Ingredients (APIs) and intermediates. The company maintains a specialized portfolio focusing on steroids, hormones, prostaglandins, and high-potency compounds, while expanding into oligonucleotides and peptides. It provides integrated Contract Development and Manufacturing Organization (CDMO) services, supporting global partners from process development to commercial-scale production. Aurisco operates advanced manufacturing sites compliant with international regulatory standards, including those of the FDA and EMA. Its technical capabilities include sophisticated chemical synthesis, fermentation, and purification technologies, designed to meet the requirements of global healthcare innovators.

Recent filings

Filing Released Lang Actions
奥锐特药业股份有限公司向不特定对象发行可转换公司债券募集说明书（修订稿）
Capital/Financing Update Classification · 95% confidence The document is titled as a "募集说明书" which translates to a "Prospectus" or "Offering Circular" for the issuance of convertible bonds to unspecified investors. It contains detailed information about the bond issuance, credit ratings, risk factors, dividend policies, management commitments, and extensive financial and operational disclosures. The document is lengthy (15,000 characters) and includes detailed financial and management analysis related to the capital raising activity. This type of document is a capital/financing update related to a new bond issuance, not an annual report, earnings release, or other report types. It is not a simple announcement or a regulatory filing but a full prospectus for a financing event. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2023-08-15 Chinese
奥锐特药业股份有限公司关于向不特定对象发行可转换公司债券申请文件的审核问询函回复的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement regarding the company's response to an inquiry letter from the Shanghai Stock Exchange about the application for issuing convertible bonds to unspecified investors. It mentions regulatory review and approval processes but does not contain financial statements or detailed financial data. The document is relatively short (736 characters) and primarily serves as a disclosure of regulatory communication and status update on financing activities. This fits the category of Capital/Financing Update (CAP) rather than a full report or audit document.
2023-08-15 Chinese
天健会计师事务所（特殊普通合伙）关于奥锐特药业股份有限公司向不特定对象发行可转换公司债券申请文件的审核问询函中有关财务事项的说明
Capital/Financing Update Classification · 95% confidence The document is a detailed financial and operational disclosure related to a company's application for issuing convertible bonds to unspecified investors. It includes extensive financial data, cost breakdowns, investment scales, and benefit calculations related to specific projects and equipment purchases. The document references a regulatory inquiry from the Shanghai Stock Exchange and includes detailed financial explanations and justifications for the financing scale and project benefits. This type of document is typical of a capital raising or financing update filing, where the company provides detailed financial and operational data to support a fundraising activity. It is not an annual report, earnings release, or audit report, nor is it a simple announcement or certification. The presence of detailed financial data and project investment analysis aligns with the Capital/Financing Update category.
2023-08-15 Chinese
国浩律师（杭州）事务所关于奥锐特药业股份有限公司向不特定对象发行可转换公司债券之补充法律意见书（一）
Capital/Financing Update Classification · 95% confidence The document is a detailed legal opinion letter from a law firm regarding a company's issuance of convertible bonds to unspecified investors. It includes extensive legal and regulatory compliance checks, responses to inquiry letters from the Shanghai Stock Exchange, and detailed information about the company's business scope, administrative penalties, environmental compliance, and use of raised funds. The document is not a financial report, earnings release, or management discussion but a legal opinion related to capital raising and regulatory compliance. This fits the category of Capital/Financing Update (CAP), as it pertains to the issuance of convertible bonds and related legal opinions. The document length and detail confirm it is not a mere announcement or certification but a substantive legal opinion report.
2023-08-15 Chinese
海通证券股份有限公司关于奥锐特药业股份有限公司向不特定对象发行可转换公司债券之上市保荐书
Capital/Financing Update Classification · 95% confidence The document is titled as a "上市保荐书" (Listing Sponsorship Letter) related to the issuance of convertible bonds by 奥锐特药业股份有限公司. It contains detailed information about the issuer, the issuance scale, bond terms, financial data, risk factors, and regulatory compliance. The document is lengthy (15,000 characters) and includes substantive financial data and detailed descriptions of the bond issuance and related corporate information. This is not a simple announcement or a brief summary but a comprehensive document related to a capital market transaction involving convertible bonds. Therefore, the document fits best into the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities such as bond issuance.
2023-08-15 Chinese
奥锐特药业股份有限公司关于通过药品GMP符合性检查的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement from 奥锐特药业股份有限公司 regarding the passing of a GMP (Good Manufacturing Practice) compliance inspection by the Zhejiang Provincial Drug Administration. It details the inspection scope, dates, results, production lines, market situation of the main products, and a risk warning. The document is short (1238 characters) and serves as an official announcement of regulatory compliance rather than a financial report or detailed management discussion. It does not contain financial data, earnings, or management changes. It is not a report publication announcement since it is the announcement itself, not a notice about a report release. The content fits best under Regulatory Filings (RNS) as a general regulatory announcement about compliance and inspection results.
2023-08-07 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.